

1H22

January - June 2022

HALF-YEAR REPORT

modulight

A man's torso is shown from the chest up, overlaid with a white wireframe grid. The heart area is highlighted with a glowing red and orange wireframe, and a red dot is visible within the heart. A red line extends from the bottom left of the image towards the heart area.

Continued uncertainty in operating environment: Go-to-market strategy to be reviewed

(The figures in brackets refer to the corresponding period of the previous year. This half-year report is unaudited.)

Highlights in April-June 2022

- ❑ Modulight continued to execute the growth strategy and invest in increasing its production capacity and improving other capabilities to realize the company's long-term potential.
- ❑ Good progress with some projects. The total number of projects remained 26 (26 in the first quarter of 2022). Customer development projects continue to be affected by COVID-19 related delays and shortages in component availability.
- ❑ As a result of the change in our operating environment we will review our strategy and update especially our go-to-market strategy. The updates will be announced later this year.
- ❑ Revenue was EUR 498 (2,355) thousand. Revenue decline was driven by the uncertainty in the business environment.
- ❑ EBITDA was EUR -2,176 (1,784) thousand. Profitability was impacted mainly by low revenue.
- ❑ Operating result (EBIT) was EUR -2,610 (1,482) thousand.
- ❑ Operating result (EBIT) margin was -524.2 (62.9) % of revenue.

Highlights in January-June 2022

- ❑ Revenue was EUR 2,100 (4,560) thousand
- ❑ EBITDA was EUR -2,594 (3,158) thousand
- ❑ Operating result (EBIT) was EUR -3,480 (2,605) thousand
- ❑ Operating result (EBIT) margin was -165.7 (57.1) % of revenue

Outlook for 2022

Modulight has not issued guidance for revenue or profitability in 2022. As the company's customer projects are still distributed across varying early stages of development and predicting developments in the market remains challenging, it is difficult to forecast performance in 2022. However, we expect that changes in the operating environment caused by COVID-19 restrictions as well as macroeconomic and geopolitical uncertainty still impact our financial performance in the short term.

Webcast

Modulight's CEO Seppo Orsila will present the result in an English-language webcast, which will be held on August 19, 2022 at 10:30 am (EET). The broadcast can be followed at <https://modulight.videosync.fi/2022-1h22-results>. Questions are requested to be submitted in writing on the webcast portal. CFO Anca Guina is also present to answer questions.

Presentation materials will be available before the start of the event on the company's website at www.modulight.com/reports-presentations/.

Seppo Orsila, CEO

Our second quarter in 2022 was disappointing in light of the financial performance. We are still affected by COVID-19 related restrictions and shortages in component availability continued to impact us more than expected. Although we do not sell to or purchase from Russia, Russia's war on Ukraine causes uncertainty in our business environment and impacts our potential customers' capital expenditure and the availability of financing for some of the early-stage companies and projects.

However, our most important strategic performance indicator, the product development pipeline remained solid with 26 projects, and we received a major new order (USD 3.9 million) and several smaller ones during the quarter. At the end of the first quarter of 2022, as announced earlier, we received a strategically important order from one of the world's largest pharmaceutical companies evidencing the potential to use our technology for new indications, such as lung cancer.

Our second quarter revenue decreased to EUR 498 (2,355) thousand and our EBITDA was EUR -2,176 (1,784) thousand. The remaining COVID-19 related restrictions related to traveling and on-site visits still slowed down our customers' research projects and also impacted our sales efforts. Our sales projects are complex and often require several face-to-face meetings during a long sales cycle that typically ranges from six months to two years. This means that both positive and negative impacts may take a long time to materialize and are hard to predict.

Furthermore, revenue and profitability decreased due to global problems with basic component availability which postponed about half of our planned second-quarter deliveries. To mitigate this risk in the future, we have systematically increased our inventories. Material costs have little impact on our profitability and we do not expect a major impact from salary inflation either.

One of the highlights in the second quarter was a USD 3.9 million purchase order received from an existing U.S. private sector customer. This order supports well our strategy of expanding our offering to new indications. In this case, our technology will be applied to diagnostics, while it has already been used for the treatment of brain cancer by other customers.

We increased our IP portfolio and filed three new US patents during the second quarter. These patents are in the fields of semiconductors, biomedical imaging and diagnostics. Our newly built analytics team is working on several patent applications related to life science and we will continue building a broader overall patent portfolio.

Our strategy implementation continued through the expansion of our manufacturing capability and capacity, although we unfortunately also experienced some delays in machine deliveries. Especially suppliers from Japan continue to highlight risks with their machine deliveries and notify us of delays on a very short notice.

Our unique technology is the basis for our long-term success and we see more opportunities than ever for expanding our co-operation with existing customers and offering our technology to new customers and indications. Our strategy is well supported by the aging population trend and the need for better cancer and eye disease prevention. We are confident that in the long term, we can also achieve our financial targets of maintaining our high rate of revenue growth and a high degree of profitability, supported by our strong balance sheet which enables accelerating investments. However, we expect that changes in the operating environment caused by COVID-19, component shortages and geopolitical uncertainty still impact our financial performance in the short term. We will review our strategy, and update especially our go-to-market strategy. The updates will be announced later this year.

Key figures ¹⁾

Group (EUR1,000)	1-6/2022	1-6/2021	4-6/2022	4-6/2021	2021 ²⁾
Revenue	2,100	4,560	498	2,355	9,071
EBITDA	-2,594	3,158	-2,176	1,784	461
EBITDA-%	-123.5 %	69.2 %	-436.8 %	75.7 %	5.1 %
Operating result (EBIT)	-3,480	2,605	-2,610	1,482	-753
Operating result (EBIT) %	-165.7 %	57.1 %	-524.2 %	62.9 %	-8.3 %
Earnings from the period	-4,370	2,022	-3,145	1,150	-5,061
Earnings per share (EUR)	-0.10	0.06	-0.07	0.04	-0.15
Acquisition & scrapping of fixed and intangible assets	-5,164	-1,818	-1,536	-2,374	-9,617
Free cash from operating activities	-7,758	1,340	-3,711	-590	-9,156
Cash & cash equivalents (at the end of the period)	53,802	2,313	53,802	2,313	62,978
Net debt	-44,917	6,817	-44,917	6,817	-53,415
Gearing ratio	-62.6 %	58.1 %	-62.6 %	58.1 %	-70.1 %
Equity ratio	86.1 %	46.6 %	86.1 %	46.6 %	87.0 %
Staff at the end of the period (FTE)	72	63	72	63	52

¹⁾ Unaudited

²⁾ Audited

Progress of the product development pipeline


The product pipeline, which the company considers the most important measure of its progress, remained solid during 2Q22. During the quarter, one new project was initiated in ophthalmology with an established Swiss company, and one was ceased with an early-stage company. At the end of the second quarter, Modulight had a total of 26 projects (20) related to individual indications and applications. Good examples of the progress of existing projects include our projects on brain diagnostics and bladder cancer.

As previously communicated, Modulight is currently approaching the U.S. regulatory approval phase for a new eye photodynamic therapy (PDT) laser in partnership with a major pharmaceutical company listed on the New York Stock Exchange. Modulight currently expects to receive the FDA approval for the PDT laser in 2022. At the end of April, the FDA officials made their first audit-related visits to the company headquarters in Tampere.

	2019				2020				2021				2022	
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q
Total number of projects*	12	12	13	13	13	13	15	16	16	20	22	24	26	26

* To be listed here, a project needs to fulfill strict criteria related to its potential for commercial roll-out as well as fit the company strategy and technology focus areas. In addition to the official projects listed in the above table, Modulight continues to work on several other initiatives, and eventually, some of these are expected mature into projects.

More information about Modulight's customers



Financial development

Revenue

April-June 2022

Revenue in the second quarter was EUR 498 (2,355) thousand. The change in revenue from the comparison period was EUR -1,857 thousand or -78.9 %.

The decline in revenue was primarily due to the continued COVID-19 related organization-specific policies limiting Modulights' and customers' ability to conduct visits to necessary facilities and causing delays in certain projects, where agreed milestones could not be met and all deliveries could not be made. Additionally, deliveries were impacted by challenges related to component availability.

Modulight continues to see significant mid- and long-term demand in the market for Modulight's expertise and technology, and all project-related work during the quarter continued to be aimed at the targeted extensive commercialization. However, most of Modulight's current revenue comes from projects related to early-phase product development with customers. Invoicing is tied to the progress of project milestones, and, especially in life sciences, there is significant uncertainty associated with each intermediate phase.

Also, Russia's war on Ukraine continues to cause general geopolitical and macroeconomic uncertainty and impacts Modulight's business environment as well as customers' capital expenditure and the availability of financing. This applies especially to early-stage companies and projects. Modulight has no direct business operations in Russia, nor does it source components from there.

January-June 2022

Revenue in January-June was EUR 2,100 (4,560) thousand. The change in revenue from the comparison period was EUR -2,460 thousand or -54.0 %. The decline was due to COVID-19 restrictions and component availability challenges.

Profitability

April-June 2022

EBITDA in the second quarter was EUR -2,176 (1,784) thousand, or -436.8 (75.7) % of revenue. The operating result (EBIT) for the period was EUR -2,610 (1,482) thousand, or -524.2 (62.9) % of revenue. Earnings per share (EPS) were EUR -0.07 (0.04). Depreciations increased by EUR 133 thousand from the comparison period, and amounted to EUR 435 thousand during the quarter, due to newly acquired equipment taken into use.

The lower level of profitability was the result of a lower level of revenue and increased operational costs. Modulights' costs are now at a significantly higher level compared to the previous year, as the company has continued to execute its growth strategy.

January-June 2022

EBITDA in January-June was EUR -2,594 (3,158) thousand, or -123.5 (69.2) % of revenue. The operating result (EBIT) for the period was EUR -3,480 (2,605) thousand, or -165.7 (57.1) % of revenue. Earnings for the first half of the year were EUR -4,370 (2,022) thousand and earnings per share were EUR -0.10 (0.06) per share.

The profitability in January-June was impacted by the write-off of trade receivables of EUR 500 thousand, in addition to the above-mentioned drivers. On June 30, 2022, the total amount of trade

receivables was EUR 5,072 (8,663) thousand. The company considers risks related to trade receivables as reasonable.

Balance sheet, financing and investments

During January-June, the company continued to invest in intangible and tangible assets, which amounted to EUR -5,164 (-1,818) thousand. Free cash flow from operating activities was EUR -7,758 (1,340) thousand.

Cash and cash equivalents were EUR 53,802 (2,313) on June 30, 2022. Financial securities included in this number are considered alternative to bank deposits and are valued at fair value through profit and loss if the fair value is lower than the acquisition value.

Net debt on June 30, 2022 was EUR -44,917 (6,817) thousand, gearing -62.6 (58.1) % and equity ratio 86.1 (46.6) %. The return on equity in the first half of 2022 was -5.9 (19.1) %.

Capitalized development expenses were EUR 1,215 (743) thousand, or 19.8 (24.7) % of total operating expenses.

Personnel, management and board

The number of employees (FTE) on June 30 2022 was 72 (63) and the average number of employees during January-June 2022 was 59 (48). Personnel expenses totaled EUR 2,410 (1,809) thousand, a change of +33.3 % from the comparison period. The fluctuations of the FTE between quarters are mainly due to summer trainees' change in working time over the summer months (from part-time to full-time).

As of June 30, 2022, Modulight's Management Team was the following.

- ❑ Seppo Orsila (CEO)
- ❑ Petteri Uusimaa (CTO)
- ❑ Anca Guina (Finance Director)
- ❑ Ulla Haapanen (Marketing Manager)
- ❑ Juha Lemmetti (R&D Director)
- ❑ Kati Reiman (People & Culture Director)
- ❑ Jari Sillanpää (Sales & Service Director)
- ❑ Ville Vilokkinen (Operations Director).

Annual General Meeting

The Annual General Meeting of Modulight Corporation was held on May 2, 2022. The General Meeting approved the financial statements for 2021 and discharged the members of the Board of Directors and the company's CEO from liability for the financial year 2021. It was decided, in accordance with the proposal of the Board of Directors, that the result for the year 2021 of EUR -5,061 thousand will be transferred to retained earnings and dividends will not be paid.

The General Meeting resolved that the number of the members of Board of Directors shall be six (6). Jyrki Liljeroos was re-elected as the chairman of the Board and Seppo Orsila, Petteri Uusimaa, Kalle Palomäki, Pia Kantola and Timur Kärki were re-elected as Board Members. The remuneration report for the financial year 2021 was also approved.

Authorized Public Accounting firm Moore Rewinet Oy was elected as the Auditor of the Company for the following term of office ending at the closing of the next Annual General Meeting. Jari Paloniemi, Authorized Public Accountant, will act as the responsible auditor.

Shares and shareholders

The company has one class of shares and all shares have equal voting rights and the right to a dividend and the company's assets. The number of shares on June 30, 2022 was 42,616,936 (30,730,000).

The Group's market capitalization on June 30, 2022, was EUR 184,531 thousand, with a share price of EUR 4.33 per share.

As of June 30, 2022, Modulight Corporation had 11,312 shareholders. The members of the Board of Directors, the CEO, and the Management Team held 46.6 % of the shares and the 20 largest shareholders accounted for 87.5 % of the total number of shares. Modulight Corporation's 20 largest shareholders on June 30, 2022, are presented in the table below.

	Owner	Number of stocks	Ownership and voting rights
1	Seppo Orsila	6,205,500	14.56 %
2	Petteri Uusimaa	6,205,500	14.56 %
3	Pekka Savolainen	3,465,000	8.13 %
4	Varma Mutual Pension Insurance Company	3,276,074	7.69 %
5	Ville Vilokkinen	3,039,750	7.13 %
6	Petri Melanen	2,173,500	5.10 %
7	Mika Saarinen	1,630,125	3.83 %
8	Pekko Sipilä	1,630,125	3.83 %
9	Swedbank Robur Funds	1,590,832	3.73 %
10	Didner & Gerge Funds	1,391,078	3.26 %
11	TIN Funds	1,155,625	2.71 %
12	SEB Funds	1,072,255	2.52 %
13	Mandatum Life Insurance Company	821,800	1.93 %
14	Ancuta Guina	670,320	1.57 %
15	Hubert Jouve	649,045	1.52 %
16	Juha Lemmetti	553,140	1.30 %
17	Jyrki Liljeroos	460,950	1.08 %
18	Alcur Funds	446,647	1.05 %
19	Evli Funds	423,306	0.99 %
20	Kalle Palomäki	414,855	0.97 %

Option programs

Modulight has offered its personnel stock option programs as part of the incentive and commitment program. The company had one option program at the end of June 2022. The total number of unused options is 852,758. No options were subscribed in January–June 2022.

Outstanding option programs are presented in the table below.

Option program	Total number of options	Unused options	Subscription price EUR	Subscription period
2021	852,758	852,758	6.49	31.12.2023-31.12.2025

Assessment of short-term risks and uncertainties

The risks are primarily as stated in the IPO material and remained unchanged. However, a clear rise can be seen in the risks related to our supply chain, which has been reflected in the availability of components and can also be seen in delays in the schedules of equipment suppliers.

As mentioned previously, the risk that mostly affected Modulight's performance were related to COVID-19 restrictions, macroeconomic and geopolitical risks, as well as the component shortage which has impacted the company's deliveries. Russia's war on Ukraine has impacted the capital markets and created challenges and delays of Modulight's potential customers' capital expenditure and the availability of financing for some of the early-stage companies.

Market overview and operating environment

The medical markets relevant to Modulight Corporation are especially related to cancer treatment (oncology), ophthalmology, genetics and diagnostics.

In addition to the medical market, Modulight has identified synergistic business opportunities for the technology it offers in the markets for other specialty applications, such as telecommunications and digital printing, but also in quantum computing, modified and virtual reality, meteorological monitoring and 3D imaging.

The global oncology pharmaceutical market was USD 144 billion in 2019 and is expected to grow to USD 391 billion by 2030, corresponding to a combined annual growth rate of 9.5 percent between 2019 and 2030 (Frost & Sullivan, Global Oncology Drug Market, 2021). Although Modulight is targeting only a portion of the global oncology market, significant growth in the overall market also means a corresponding increase in demand for laser-based oncology treatments. Growth in the oncology market is driven in particular by an aging population worldwide. Age is known to be a major factor in the increase in the incidence of cancers.

The global ophthalmic treatment market was USD 29.5 billion in 2018. The market is expected to grow at a combined annual growth rate of 6.2 percent to approximately USD 48 billion in 2026. Modulight believes that the growth of the global eye care market will be supported primarily by the continuing increase in ophthalmic diseases with an aging population and increasing R&D investment in the development of treatments for ophthalmic diseases.

In the fields of genetics and diagnostics, the global combined market for next-generation sequencing, endoscopes, and flow cytometry is expected to grow from the current USD 21 billion to tens of billions of dollars by the end of the decade. One of the main growth factors in the genetics and diagnostics market is the need for personalized drug therapies for the treatment of cancers. Other important drivers for growth include the need for scalable cloud-based care solutions.

Recent changes in the operating environment

Russia's war on Ukraine has impacted the capital markets and created challenges and delays of Modulight's potential customers' capital expenditure and the availability of financing especially for

some of the early-stage companies. Our operating environment continued to be affected by COVID-19 related restrictions and shortages in component availability, which has negatively impacted delivery schedules.

Strategy

Modulight is in the process of reviewing its strategy and will announce it during 2022. The previously announced targets and long-term goals are described below.

Modulight Corporation has 20 years of experience in medical applications, laser and optics design and production. The company supplies biomedical lasers for a variety of medical applications, such as oncology, ophthalmology and genetics, as well as other diagnostics. The company also offers customized and lasers for well-selected customer value-added applications, such as telecommunications, digital printing, environmental detection and imaging.

The company strives to increase the total number of projects in the product development pipeline. As a result of the projects, prototypes are created for the commercial introduction of the products. The products developed in the projects are made under the company's own brand, and the company also mainly owns the related intellectual property rights. Generally, projects have significant synergies with each other.

In addition, the company has identified the following strategic priorities to advance its profitable growth strategy.

- ❑ Expanding the product range to other indications: Modulight intends to expand its product range to other indications (the purpose of treatment, i.e. certain cancers) and plans to expand the use of its medical device platform.
- ❑ Increasing production capacity: Modulight has decided to increase its capabilities and production capacity to meet increased demand through an ongoing EUR 23 million investment program.
- ❑ Geographic expansion: Modulight aims to expand its business in key regions in the United States and in selected markets in Asia, such as China and Japan.
- ❑ Expansion opportunities in the field of cloud analytics: Modulight is developing its cloud-based analytics services to further improve the therapeutic efficacy and final treatment results of treatments provided with the company's equipment.
- ❑ Continued investment in laser technology: Modulight will continue to invest in high-power single-laser technology and intends to further improve its position over its competitors.

Long-term goals

The company's long-term financial goal is to maintain strong revenue growth and strong profitability. In addition, the company's business goal is to advance the large-scale commercial introduction of the products with its three customers by the end of 2023.

Most of Modulight's current revenue comes from products under development, and the company determines that extensive commercial deployment has taken place when the company's revenue for that product/customer exceeds EUR 10 million.

In the coming years, Modulight will focus on financing the growth and development of its business. The company will follow a very strict dividend policy, which is tied to the company's result and financial position. The company estimates that it will not distribute dividends or will distribute them to a very small extent in the short to medium term.

Events after the reporting period

There have been no significant events since the review period.

Financial reporting in 2022

During the year 2022, Modulight will publish the financial information as follows:

- ❑ 3Q22 Business review (1-9/2022): October 20, 2022

Tampere, August 19, 2022

Board of Directors

Modulight Corporation

For further information, please contact:

CEO: Seppo Orsila m. +358 40 830 4671

IR: Ulla Haapanen m. +358 40 830 4676

Email: ir@modulight.com

Certified Adviser: Danske Bank A/S, Finland Branch, m. +358 40 414 5358

www.modulight.com

Twitter: [@modulight](https://twitter.com/modulight)

Modulight in brief

Modulight Corporation is a biomedical laser company that designs and manufactures products for oncology, ophthalmology and genetics. The company also provides solutions for selected high value-add applications including quantum computing and digital press. The company's products include medical devices, subsystems, software, cloud services and specialized semiconductors. Modulight's products are used worldwide by many Fortune 500 companies, international pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland. www.modulight.com

Table section 1 January - 30 June 2022

Accounting principles for the half-year report

The figures in this report are unaudited unless otherwise stated. The financial figures have been prepared in accordance with Finnish Accounting Standards (FAS).

Consolidated income statement (FAS)

EUR 1,000	1-6/2022	1-6/2021	4-6/2022	4-6/2021	2021
TURNOVER	2,100	4,560	498	2,355	9,071
Change in inventory	-20	19	-56	19	329
Manufacturing for own use	1,215	743	630	438	1,579
Other operating income	545	1,059	279	689	1,345
Raw materials and services					
Raw materials and consumables					
Purchases during financial year	-1,416	-575	-909	-430	-1,596
Change in inventory	866	164	525	166	406
External services	-236	-148	-119	-104	-362
Total raw materials and services	-786	-560	-503	-368	-1,552
Staff expenses					
Wages and salaries	-2,055	-1,479	-1,112	-766	-3,199
Social security expenses					
Pension expenses	-361	-281	-190	-143	-538
Other social security expenses	6	-48	42	-25	-142
Total staff expenses	-2,410	-1,809	-1,260	-933	-3,880
Depreciation, amortization and reduction in value					
Depreciation and amortization according to plan	-886	-553	-435	-302	-1,214
Other operating expenses	-3,239	-856	-1,764	-416	-6,432
OPERATING PROFIT	-3,480	2,605	-2,610	1,482	-753
Financial income and expenses					
Other interest income and financial income	14	2	10	2	7
Interest and other financial expenses	-904	-84	-544	-51	-4,317
Total financial income and expenses	-889	-82	-534	-49	-4,310
PROFIT (LOSS) BEFORE APPROPRIATIONS AND TAXES	-4,369	2,523	-3,145	1,433	-5,063
Income taxes	-1	-501		-283	1
PROFIT (LOSS) OF THE FINANCIAL YEAR	-4,370	2,022	-3,145	1,150	-5,061

Consolidated balance sheet (FAS)

EUR 1,000	30.6.2022	30.6.2021	31.12.2021
ASSETS			
Non-current assets			
Intangible assets			
Development expenditure	6,320	5,056	5,490
Total intangible assets	6,320	5,056	5,490
Fixed assets			
Buildings	2,870	2,806	2,903
Machinery and equipment	6,802	813	5,686
Advance payments	4,100	1,371	1,734
Total fixed assets	13,771	4,990	10,324
Total non-current assets	20,091	10,047	15,814
Current assets			
Inventory			
Raw materials and consumables	1,346	543	785
Finished products	629	33	343
Total Inventory	1,975	576	1,128
Debtors			
Short-term			
Trade debtors	5,072	8,663	5,636
Other debtors	1,584	1,114	1,491
Prepayments and accrued income	770	2,475	468
Total short-term debtors	7,426	12,252	7,596
Financial securities	52,989		62,469
Cash and cash equivalents	813	2,313	508
Total current assets	63,204	15,141	71,702
TOTAL ASSETS	83,295	25,188	87,515

EQUITY AND LIABILITIES	30.6.2022	30.6.2021	31.12.2021
Equity			
Equity capital	80	18	80
The invested unrestricted equity fund	75,334	3,284	75,334
Retained earnings	714	6,411	5,800
Earnings from the period	-4,370	2,022	-5,061
Total equity	71,758	11,735	76,153
Liabilities			
Non-current liabilities			
Capital loan		80	
Loans from financial institutions	7,618	8,089	8,217
Total non-current liabilities	7,618	8,168	8,217
Current liabilities			
Capital loan			80
Loans from financial institutions	1,267	962	1,267
Advances received	166	318	112
Accounts payable	698	579	727
Other liabilities	102	69	108
Accrued expenses	1,686	3,358	853
Total current liabilities	3,918	5,286	3,146
Total liabilities	11,537	13,454	11,363
TOTAL EQUITY AND LIABILITIES	83,295	25,188	87,515

Consolidated cash flow statement (FAS)

Cash flow from operating activities	1-6/2022	1-6/2021	4-6/2022	4-6/2021	2021
Operating result	-3,480	2,605	-2,610	1,482	3,247
Depreciation & amortization	886	553	435	302	1,214
Net interests	-889	-82	-534	-49	-4,310
Change in inventory	-847	-183	-469	15	-735
Change in short-term receivables	133	-2,187	335	-1,217	-1,531
Change in short-term liabilities	889	-70	355	88	-2,593
Tax on profit	-1	-501	0	-283	1
Net cash from operations (A)	-3,309	135	-2,488	338	-4,707
Cash flow from investing					
Investments in fixed and intangible assets	- 2,799	-1,818	-1,378	-2,374	-9,617
Advance payments	-2,365	-1,371	-158		
Net cash from investing (B)	-5,164	-3,189	-1,536	-2,374	-9,617
Cash flow from financing					
Change in interest-bearing debts	-678	3,422	-333	2,766	75,904
Dividends paid					-615
Net cash from financing (C)	-678	3,422	-333	2,766	75,290
Net cash flow (A+B+C)	-9,151	368	-4,357	730	60,965
Cash at the beginning of the period	62,978	1,784	58,185	1,615	1,784
Exchange rate differences	-25	161	-26	-32	228
Cash at the end of the period	53,802	2,313	53,802	2,313	62,978

Changes in equity items and distributable funds

Restricted equity (EUR 1,000)	1-6/2022	1-6/2021
Share capital 1.1.	80	18
Share capital increases during the financial year		
Share capital 30.6.	80	18
Total restricted equity 30.6.	80	18
Unrestricted equity (EUR 1,000)		
Reserve for invested unrestricted equity 1.1.	75,334	3,284
Increases in the invested unrestricted equity fund		
Reserve for invested unrestricted equity 30.6.	75,334	3,284
Profit (loss) for the previous financial years 1.1.	739	6,249
Exchange rate differences	- 25	161
Dividends distributed during the financial year		
Profit (loss) for the previous financial years 30.6.	714	6,410
Profit of the financial period	-4,370	2,022
Total non-restricted equity 30.6.	71,678	11,716
Total equity on 30 June 2022	71,758	11,734

Calculation formulas for key figures

Key figures	Definition	Reason for the use
Growth of revenue-%	$(\text{Revenue for the period} - \text{The revenue of the previous reference period}) / \text{Previous revenue for the period}$	Revenue growth is an indicator to measure the growth of the Company
EBITDA	Operating result before depreciation, and amortization	EBITDA is an indicator to measure the operational performance of the Company
EBTIDA-%	$\text{EBITDA} / \text{Revenue}$	Operating margin is an indicator to measure the operational performance of the Company
Operating result	Operating result as presented in the income statement	Operating result is an essential indicator for the understanding of the Company's financial performance
Operating result-%	$\text{Operating result} / \text{Revenue}$	Operating result is an essential indicator for the understanding of the Company's financial performance
Earnings per share	Earning from the period / weighted average number of outstanding shares during the period	Indicator describes the distribution of operating result to individual shares
Acquisition & scrapping on fixed and intangible assets	Acquisition & scrapping of fixed and intangible assets as presented in the statement of cash flow	Indicator produces more information on the cash flow needs for operational investments
Free cash flow operating activities	$\text{EBITDA} - \text{Acquisitions \& scrapping of fixed and intangible assets as presented in the statement of cash flow}$	Indicator produces information of the cash flow which the Company is able to generate after operational investments
Net debt	Interest-bearing debt - Cash and cash equivalents (at the end of the period)	Net debt is an indicator to measure the total external debt financial of the Company
Gearing ratio	$(\text{Interest-bearing debt} + \text{Cash and cash equivalents (at the end of the period)}) / \text{Equity}$	Indicator for the management to track the Company's level of equity
Equity ratio	$\text{Equity} / \text{Total Equity}$	Indicator for the proportion of the Company's assets that have been financed with equity

modulight

www.modulight.com